In secondary tauopathies such as AD, tau dysregulation is thought to be an effect of other pathological proteins, most notably the aggregation of amyloid-β (Aβ) peptides in the senile plaques of AD patients [7]. The gene discussed is MAPT; the disease is Alzheimer disease.